Home > Neurology > ECTRIMS 2019 > Optimising Long-Term Benefit of MS Treatment > Late-breaking: Ofatumumab versus teriflunomide in relapsing MS

Late-breaking: Ofatumumab versus teriflunomide in relapsing MS

Conference
ECTRIMS 2019
Trial
Phase 3, ASCLEPIOS
Ofatumumab is the first fully human anti-CD20 mAb, which is under development for the treatment of MS. Ofatumumab binds to CD20, resulting in B-cell depletion and reduced B- and T-cell interactions, which may reduce inflammation in the central nervous system. Anti-CD20 therapy may preserve pre-existing humoral immunity and B-cell reconstitution [1]. Two phase 3 trials, identical in design and conducted in parallel, ASCLEPIOS I and II (n=1,881 totally), evaluated the effect of ofatumumab in patients with relapsing MS. Ofatumumab demonstrated significant reduction of adjusted annualised relapse rate (ARR): ASCLEPIOS I: 0.22 in teriflunomide group vs 0.11 in ofatumumab group (relative reduction of 50.5%; P<0.001); and ASCLEPIOS II: 0.25 in teriflunomide group vs 0.10 in ofatumumab group (relative reduction of 58.5%; P<0.001, see Figure) [2]. Figure. Ofatumumab demonstrated significant reduction in ARR (primary...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on